10-K: MaxCyte 2025 Annual Report: Losses Widen Amid Restructuring

MaxCyte reported a wider net loss of $44.6 million in 2025, driven by decreased core revenue and a workforce reduction, despite strategic acquisition and platform expansion.

Summary

• Net loss widened to $44.6 million in 2025 from $41.1 million in 2024.
• Total revenue decreased by 15% to $33.0 million in 2025 from $38.6 million in 2024.
• Core revenue decreased by 9% to $29.6 million in 2025, primarily due to a 15% decrease in PA and consumable sales and a 13% decrease in license revenue.
• SPL program-related revenue decreased by 44% to $3.4 million in 2025 from $6.1 million in 2024, reflecting variability in milestone achievements.
• Gross margin remained strong at 81% in 2025, a slight decrease from 82% in 2024.
• Research and development expenses decreased by 6% to $20.8 million in 2025.
• Sales and marketing expenses decreased by 29% to $18.9 million in 2025, primarily due to headcount reduction.
• General and administrative expenses decreased by 5% to $28.1 million in 2025.
• Incurred $3.1 million in restructuring expense due to a workforce reduction plan, impacting approximately 34% of the global workforce.
• Recognized a non-cash goodwill impairment charge of $3.6 million in 2025 related to the SeQure acquisition.
• Acquired SeQure Dx in January 2025, expanding service offerings for gene editing assessment.
• Launched the DTx electroporation platform in February 2026.
• The installed base of electroporation instruments grew to over 857 globally as of December 31, 2025 (from 760 in 2024).
• Maintains 31 active Strategic Platform Licenses (SPLs) with commercial cell therapy developers, with 13 programs in clinical development and one in commercial stage as of December 31, 2025.
• Total potential pre-commercial milestone opportunity across 31 SPLs is greater than $2 billion, with over $130 million from 13 active clinical programs if all achieve regulatory approvals; over $30 million in milestone revenue received to date.
• Cash and cash equivalents and short-term investments totaled $103.0 million as of December 31, 2025.
• Received a Nasdaq notice on March 16, 2026, for non-compliance with the minimum bid price requirement ($1.00 per share for 30 consecutive trading days).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution due to widening net losses, a significant year-over-year revenue decline, and a goodwill impairment charge. While strategic acquisitions and a strong gross margin are noted, the Nasdaq delisting notice adds a notable concern regarding market perception and compliance.

Positives

• Maintained a strong gross margin of 81% in 2025, indicating efficient cost management relative to revenue.
• Increased the installed base of electroporation instruments to over 857 globally, demonstrating continued market penetration and customer adoption.
• Expanded Strategic Platform Licenses (SPLs) to 31 active agreements, with a significant potential for future pre-commercial milestone payments exceeding $2 billion.
• The acquisition of SeQure Dx in January 2025 strengthens service offerings and expands market reach in gene editing assessment, a critical area for cell and gene therapies.
• Launched the new DTx electroporation platform in February 2026, indicating ongoing product innovation and portfolio expansion.
• The FDA Master File and equivalent Technical Files have been referenced in over 75 clinical trials, providing a regulatory advantage and potentially accelerating customer development timelines.
• The workforce reduction plan implemented in 2025 is expected to decrease operating expenses in 2026, aiming to improve cost structure.

Negatives

• Net loss widened to $44.6 million in 2025, compared to $41.1 million in 2024, indicating increasing unprofitability.
• Total revenue decreased by 15% year-over-year, from $38.6 million in 2024 to $33.0 million in 2025.
• Core revenue decreased by 9%, primarily driven by a 15% decrease in PA and consumable sales and a 13% decrease in license revenue.
• SPL program-related revenue significantly decreased by 44% to $3.4 million in 2025, reflecting fewer milestone achievements.
• Incurred $3.1 million in restructuring expense due to a workforce reduction of approximately 34% of the global workforce.
• Recognized a $3.6 million non-cash goodwill impairment charge in 2025.
• Received a Nasdaq notice on March 16, 2026, for non-compliance with the minimum bid price requirement, posing a risk to continued listing.
• Interest income decreased by 28% to $7.3 million in 2025, primarily due to decreases in interest rates and cash and investment balances.

Risks

• Incurred significant losses since inception and expects to incur losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• Highly dependent on a limited number of product offerings (instruments, PAs), with revenue prone to quarterly fluctuations and customer clinical development progress, which is outside of the company's control.
• Business is dependent on adoption of products by biopharmaceutical companies and academic institutions; reluctance to change current practices could negatively affect business, financial condition, prospects, and results of operations.
• May be unable to compete successfully against existing or future competitors, some of whom have substantially greater financial and other resources.
• Failure to maintain and expand current SPL agreements and enter into new agreements that generate marketed licensed products could adversely affect the business.
• Customers may not achieve projected development, regulatory milestones, or other anticipated key events in expected timelines or at all, or may discontinue programs, which could have an adverse impact on the business and stock price.
• Dependence on a limited number of customers for revenue; the loss of any of which could have an adverse impact on the business (one customer accounted for 26% of total revenue in 2025, top five for 42%).
• Future acquisitions could disrupt business, cause dilution to stockholders, or harm financial condition and operating results.
• Dependence on continued supply of high-quality components and raw materials from third-party suppliers; shortages or higher prices could impact production and ability to meet demand.
• Limited experience manufacturing PAs; inability to successfully and consistently manufacture high-quality commercial quantities could limit growth.
• Inability to accurately forecast customer demand for products and manage inventory could harm operating results.
• Failure to successfully develop new products, adapt to rapid technological change, or respond to competitors' introductions could cause business to suffer.
• New product development involves a lengthy and complex process, and the company may be unable to develop or commercialize products on a timely basis or at all.
• Complex systems may contain defects not detected until deployed by customers, which could harm reputation, increase costs, or reduce sales.
• Failure or perceived failure to comply with existing or future laws, regulations, contracts, and other obligations related to data privacy and security could harm the business.
• Delays in filing or obtaining, or inability to obtain or retain, acceptance of FDA Master File and equivalent foreign filings could negatively impact SPL customers' progress and revenues.
• May need additional funding and may be unable to raise capital when needed, which could require delaying, reducing, eliminating, or abandoning commercialization efforts or product development programs, or diluting existing stockholders.
• International operations may raise additional risks, including compliance with foreign regulatory requirements, geopolitical tensions, and foreign currency exchange rate risk.
• Failure to offer high-quality customer service could harm business and reputation.
• Customers' products or product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial potential, or result in negative consequences.
• Collaborations or licensing arrangements, joint ventures, strategic alliances, partnerships, or other strategic investments may fail to produce anticipated benefits and adversely affect operations.
• Business disruptions (e.g., earthquakes, power shortages, public health emergencies, geopolitical conflicts) could seriously harm future revenue and financial condition and increase costs.
• Information technology systems, or those of third parties, could be compromised, leading to adverse consequences from cybersecurity incidents.
• Highly dependent on senior management team and key personnel; inability to attract and retain personnel necessary for success could harm the business.
• May experience difficulties in managing anticipated growth, which could harm future revenue and operating results.
• Officers, employees, independent contractors, consultants, and commercial partners may engage in misconduct or make significant errors, which could create liability.
• Exposure to substantial product liability claims that exceed resources, limit sales, and commercialization.
• Customers' failure to safely and appropriately use products, or inability to train customers, could negatively impact reputation and sales.
• Litigation and other legal proceedings may harm the business, financial condition, and divert management attention.
• May be subject to damages from claims of wrongful use or disclosure of alleged trade secrets of employees' former employers.
• Insurance policies are expensive and protect only from some business risks, leaving significant uninsured liabilities.
• Majority of operations conducted at a single location; any disruption could negatively impact operations and increase expenses.
• Changes in U.S. patent law could diminish the value of patents, impairing ability to protect products.
• May be obligated to disclose proprietary technology to customers, limiting intellectual property protection.
• Inability to maintain Nasdaq listing due to minimum bid price requirement could adversely affect liquidity and market price.
• Price of common stock is likely to be volatile and may fluctuate due to factors beyond control.
• If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about the business, the price of common stock and trading volume could decline.
• Requirements of being a public company in the United States may strain resources, increase operating costs, and divert management's attention.
• Increasing scrutiny and evolving expectations from stakeholders regarding environmental, social, and governance (ESG) practices may impose additional costs or risks.
• Future sales of common stock in the public market could cause share price to fall.
• Does not expect to pay dividends on common stock in the foreseeable future; capital appreciation is the sole source of gain.
• Reduced reporting requirements as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial results or fraud.

Future Outlook

MaxCyte expects to continue incurring net losses for the foreseeable future as it focuses on growing commercial sales, expanding sales teams, scaling manufacturing operations, and investing in research and development for new and enhanced products. Operating expenses are anticipated to decrease in 2026 due to the recent restructuring but are expected to increase in absolute dollars in periods beyond 2026. The company projects ending 2026 with at least $136 million in total cash, cash equivalents, and investments.

Management Comments

• "We believe that our current facilities are adequate and suitable to meet our current requirements. We may need to obtain additional facility space to meet future needs as our operations grow over time. We believe we will be able to obtain additional space on acceptable and commercially reasonable terms if and as required."
• "We believe our existing cash balances and cash receipts generated from sales of our products will be sufficient to meet our anticipated cash requirements for the foreseeable future. However, we may need additional funding sooner than we expect and our business and future funding requirements can change unpredictably due to a variety of factors, including acquisitions, which could affect our funding needs or cash flows from operations."
• "We expect to end 2026 with at least $136 million in total cash, cash equivalents and investments."

Industry Context

StockSavvy.ai notes that MaxCyte operates in the rapidly expanding cell therapy market, which has seen significant investment, with the Alliance for Regenerative Medicine (ARM) estimating $11.1 billion raised in 2025 and over 2,120 active clinical trials. The company's proprietary Flow Electroporation technology and ExPERT platform address critical industry needs by offering a non-viral delivery method, which is gaining traction due to limitations and concerns associated with traditional viral vectors (e.g., payload capacity, toxicity, cost, and manufacturing bottlenecks). The acquisition of SeQure Dx positions MaxCyte to offer comprehensive gene editing assessment services, aligning with the industry's increasing demand for robust analytical tools to support regulatory approvals and early-stage development of complex cell and gene therapies.

Comparison to Industry Standards

• MaxCyte's ExPERT platform is utilized by an SPL customer for the first FDA-approved ex-vivo cell therapy in December 2023, demonstrating a leading position in enabling commercial-stage non-viral cell therapies, a significant benchmark in the industry.
• The platform's ability to engineer cells from tens of thousands to tens of billions in 30 minutes or less, while maintaining high efficiency and viability, positions it as a high-performance solution compared to competitors like Lonza Group AG, Thermo Fisher Scientific Inc., Miltenyi Biotec, Bio-Rad Laboratories, Inc., and Harvard Biosciences Inc.
• The established FDA Master File and equivalent Technical Files, referenced in over 75 clinical trials, provide a distinct competitive advantage by potentially accelerating regulatory submissions for customers, a critical factor in the highly regulated biopharmaceutical development landscape.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened legal proceedings that are believed to have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• Sold $34,000 in products and services to a customer in 2025 whose Board of Directors includes a member also serving on MaxCyte's Board of Directors.
• Had $6,000 in accounts receivable from this customer as of December 31, 2025.
• Entered into a consulting agreement effective January 1, 2024, with a Board member to provide services for up to $150,000 over 12 months, incurring $102,000 in 2024.
• Sold $86,000 in products to a customer in 2024 whose Chief Executive Officer is a member of MaxCyte's Board of Directors.

Stakeholder Impact

• Shareholders face potential dilution from future equity capital raises, increased stock price volatility due to financial performance and Nasdaq listing concerns, and no anticipated dividend income.
• Employees experienced a workforce reduction of approximately 34% in 2025, which could impact morale and increase workload for remaining staff, though equity incentive plans are in place to attract and retain talent.
• Customers benefit from continued investment in R&D and new product launches (e.g., DTx), but their own clinical development progress and funding constraints can directly impact MaxCyte's revenue from SPLs.
• Suppliers face risks due to MaxCyte's dependence on a limited number of third-party suppliers for key components, which could lead to supply chain disruptions.
• Creditors may view the widening net losses and potential need for additional financing as indicators of increased financial risk, potentially affecting future borrowing terms.

Next Steps

• Continue to invest in research and development to support customers, develop new uses for existing technology, and create improved/new offerings.
• Further expand commercial infrastructure, including sales force and field application scientists, to drive adoption and support global brand.
• Expand international operations, particularly in the Asia-Pacific region, initially through distributors and then potentially direct sales.
• Develop and launch new Processing Assemblies (PAs) that target previously unserved subsegments across bioprocessing and cell therapy markets.
• Address the Nasdaq minimum bid price non-compliance by meeting or exceeding $1.00 per share for ten consecutive trading days prior to September 14, 2026.
• Douglas J. Swirsky will continue to serve as CFO through May 31, 2026 (or earlier if a new CFO starts), then transition to a Senior Advisor to the CEO role until May 31, 2026, followed by an 18-month consulting period.

Key Dates

Recommendation

The company reported a significant decline in total revenue and core revenue, coupled with a widening net loss and substantial one-time charges from restructuring and goodwill impairment. The Nasdaq minimum bid price non-compliance notice adds a serious concern regarding the company's market standing and potential liquidity. While strategic acquisitions and a strong gross margin are noted, the overall financial deterioration and operational challenges present a negative outlook for the stock in the near term, suggesting investors should consider selling.

Keywords

Cell engineering, Cell therapy, Gene therapy, Electroporation, ExPERT platform, Biopharmaceutical, Strategic Platform Licenses, SEC filing, 10-K, MaxCyte, MXCT, Biotechnology, Life sciences, R&D, Financial results, Corporate governance, Risk management, Nasdaq, SeQure Dx, Goodwill impairment, Workforce reduction